[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652924":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":29,"responsibleParty":48,"collaborators":20,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":76,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Instituto de Investigación Sanitaria Aragón","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PURE cohort","EXPERIMENTAL","Patients candidates for adjuvant pelvic (Cht)EBRT treatment (+\u002F- vaginal cuff brachytherapy), categorized by Intermediate-high risk and high risk primary endometrial cancer based on recent ESGO\u002FESTRO\u002FESMO Guidelines (2025).",[13],"Radiation: Ultra-hypofractionation schedule of 27.5Gy in 5 fractions on image-guided adjuvant pelvic IMRT\u002FVMAT radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Ultra-hypofractionation schedule of 27.5Gy in 5 fractions on image-guided adjuvant pelvic IMRT\u002FVMAT radiotherapy","Classically, the dose prescribed for adjuvant treatment of endometrial cancer were 45-50Gy in conventional fractionation 1.8Gy\u002Ffx, in a total 25-28fx. The shedule proposed on this prospective cohort of 27.5Gy in 5 fractions on image-guided adjuvant pelvic IMRT\u002FVMAT radiotherapy.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Marta Gimeno Morales, MD, PhD","CONTACT","+34 976 76 55 00","ucmorapure@gmail.com",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":20},"Reyes Ibañez Carreras, PhD",[30],{"facility":31,"status":32,"city":33,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Unidad Clínica Multihospitalaria de Oncología Radioterápica de Aragón (UCMORA)","RECRUITING","Zaragoza","50009","Spain","ES",{"type":38,"coordinates":39},"Point",[40,41],-0.87734,41.65606,{"lat":41,"lon":40},[44],{"name":23,"role":24,"phone":45,"phoneExt":46,"email":47},"+34 976 765500","142550","mgimenom@salud.argon.es",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","MARTA GIMENO MORALES","PhD, MD. Radiation Oncology Staff from UCMORA. Clinical Professor.","100652924","pelvic-ultra-hypofractionated-adjuvant-radiotherapy-for-endometrial-cancer-pure-cohort-100652924",false,"NCT07779109","Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)","Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for High-Intermediate and High-Risk Endometrial Cancer: A Prospective Multicenter Phase II Safety Cohort Study","PURE-cohort","Inclusion Criteria:\n\n1. Aged \\> 18 years.\n2. Histologically confirmed diagnosis of endometrial cancer post hysterectomy: endometrial adenocarcinoma, serous or clear cell carcinoma, or carcinosarcoma or dedifferentiated carcinoma.\n3. Patients candidates for adjuvant pelvic (Cht)EBRT treatment (+\u002F- vaginal cuff brachytherapy), categorized by Intermediate-high risk and high risk primary endometrial cancer based on recent ESGO\u002FESTRO\u002FESMO Guidelines (2025).\n4. Patient is willing and able to give informed consent to participate in this clinical trial.\n5. Patient must be willing and able to complete the QLQ-C30 questionnaire with EN-24 companion as described in the study protocol\n6. Possibility of fiducial marker placement on vaginal vault.\n7. Dosimetric feasibility based on OAR constraint and targets objective\n\nExclusion Criteria:\n\n1. Prior pelvic or abdominal radiation therapy delivered.\n2. Inflamatory bowel disease of other contraindication to pelvic radiotherapy.\n3. Previous abdominal or pelvic complicated surgery.","FEMALE","18 Years","110 Years",{"count":64,"type":65},50,"ESTIMATED","INTERVENTIONAL",[68],"NA","The PURE trial is a prospective multicenter phase II study evaluating the safety and feasibility of ultra-hypofractionated adjuvant pelvic radiotherapy in patients with high-intermediate-risk and high-risk endometrial cancer following surgery. The study investigates a treatment regimen consisting of 27.5 Gy delivered in five fractions using modern image-guided IMRT\u002FVMAT techniques. The primary objective is to assess acute gastrointestinal and genitourinary toxicity according to CTCAE version 5.0.",[71,72,73,74,75],"SBRT","Radiation Therapy","Endometrial Cancer","Endometrial Cancer Stage III","High-risk Endometrial Cancer",[77,78,79,80,81],"Endometrial cancer","Ultrahypofractionated Radiation Therapy","Postoperative pelvic radiation therapy","Postoperative pelvic sbrt","high-risk endometrial cancer","2026-08-18",{"date":84,"type":85},"2026-08-21","ACTUAL",{"date":87,"type":85},"2026-03-30",{"date":89,"type":65},"2035-03-30",{"name":5,"class":6},1]